The described NLRP3 inflammasome activation in B-cell NHLs can be, so far, attributed to three parameters: (a) genetic alterations in genes encoding for NLRP3 inflammasome-associated molecules, which favor the upregulation of the NLRP3 inflammasome pathway; (b) aberrations in factors regulating B-cell development that induce the NLRP3 inflammasome pathway; and (c) persistent inflammatory signaling and NLRP3 inflammasome activation in immune cells of the lymphoma microenvironment favoring B-cell malignant transformation. The gene discussed is NLRP3; the disease is lymphoma.